Introduction {#s1}
============

Hypertension (MIM \#14500) is one of the most common chronic diseases, and the most frequent reason for people to consult their doctor and take medication. Hypertension can burst a blood vessel or/and accelerate narrowing of arteries in the brain to cause a stroke which, if not lethal, can result in many catastrophic complications such as paralysis, aphasia, coma and so forth. The damage to the brain cannot be repaired, so the only rational approach is prevention. Hypertension is a major risk factor for the development of stroke. In 1964, it was first demonstrated that antihypertensive agents could reduce the risk of strokes [@pone.0057854-Hamilton1]. It is well known that lowering blood pressure decreases the risk of stroke in people with moderate to severe hypertension [@pone.0057854-Liu1]. There are eight classifications of antihypertensive agents in use today: α-adrenergic blockers, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists, antiadrenergic agents, β-adrenergic blockers or β blockers, calcium channel blockers (CCBs), diuretics, and vasodilators. Despite the widespread use of blood-pressure-lowering agents which one is better against the development of stroke is unclear [@pone.0057854-National1]. Controlling blood pressure in the patients with hypertension or/and stroke has important clinical implications including improved prognosis, reduced mortality and so on [@pone.0057854-Song1]. Angiotensin-converting enzyme inhibitors, β-adrenergic blockers, calcium channel blockers and diuretics are used extensively and listed as the first-line agents in the 1989 WHO/International Society of Hypertension Guidelines [@pone.0057854-Hansson1]. Because each study may have insufficient power to detect the effect of calcium channel blockers against stroke in the patients with hypertension; a meta-study to accumulate data from different studies may address this issue, and the specific effects of CCBs against stroke in patients with hypertension as compared to no treatment and other antihypertensive drug classes are not known. Therefore, the major goal of this work was to perform a systematic review and a meta-analysis of the published data and to figure out whether calcium-channel blockers are better than other first-line antihypertensive agents in the prevention of stroke, as well as to quantify the potential heterogeneity between different studies.

Methods {#s2}
=======

Data Sources {#s2a}
------------

The PUBMED, MEDLINE, EMBASE, OVID, CNKI, MEDCH, and WANFANG databases were searched for trials published in English or Chinese during the period January 1, 1996 to July 31, 2012. In addition, all references cited in these studies and previously published review articles were reviewed to identify additional works not indexed by the above databases. Search terms were "antihypertensive agents", "placebo", "hypertension", "diuretics", "beta-blockers" or "β-adrenergic blockers", "angiotensin-converting-enzyme inhibitors", "calcium channel blockers", "vasodilator agents", and "stroke". Bibliographies of studies were also reviewed.

Study Selection {#s2b}
---------------

A total of 177 published studies were identified using the screening procedure shown in [Figure 1](#pone-0057854-g001){ref-type="fig"} (see Supplementary Information online). Among them, fifty-eight are systematic reviews and meta-analyses, one hundred and nineteen are randomized controlled trials. After searching, the following information was extracted: author, ethnicity of research subjects, year of publication, numbers of hypertension- and stroke-cases, medicine of treatment, age of patients, and years of followed-up. Studies were eligible for inclusion if they were randomized controlled trials and reported on stroke risk associated with the current use of the first-line antihypertensive agents in population settings.

![A schematic diagram for the search strategy of published reports.](pone.0057854.g001){#pone-0057854-g001}

Quality Assessment {#s2c}
------------------

Eligible studies must meet the following inclusion criteria: (1) with original data being independent among studies if more than one studies have overlapping subjects, only the study with bigger/biggest sample size was selected; (2) with the numbers of hypertension- and stroke-cases clearly provided; (3) with data of the first-line antihypertensive agents and/or placebo; (4) with the research design of randomized controlled trials, which is the best approach to evaluating new treatments, to challenging the efficacy of the old one, and to comparing the efficacy of different treatments [@pone.0057854-Hill1]--[@pone.0057854-Hill2]. All the available information was independently extracted by two investigators and no inconsistency was discovered. The quality assessment of evidence and an overall risk of bias assessment for each included study were evaluated by GRADEprofiler software version 3.2.2 and RevMan version 5.0 (see Supplementary Information online), respectively.

Statistical Analysis {#s2d}
--------------------

Publication bias was detected by Egger's linear regression test, which measures funnel plot asymmetry on the scale of odds ratio (OR) [@pone.0057854-Egger1]. Heterogeneity between studies was tested by Cochran's Q-statistic test [@pone.0057854-Colditz1] and *I* ^2^ = 100% × (Q-df) ÷ Q [@pone.0057854-Higgins1], respectively. The *I* ^2^ metric is independent of the number of studies in the meta-analysis, and ranges between 0 and 100% (*I* ^2^\<25%: no heterogeneity; *I* ^2^ = 25%--50%: moderate heterogeneity; *I* ^2^ = 50%--75%: high heterogeneity; *I* ^2^\>75%: extreme heterogeneity). Heterogeneity was considered statistically significant when *p*\<0.05 [@pone.0057854-Deeks1]. If results were heterogeneous, the random effects model was used for meta-analysis. OR was pooled using the method of DerSimonian and Laird, and 95% confidence interval (CI) was constructed using Woolf's method. The statistical analysis was conducted by the statistical package RevMan version 5.0 (The Cochrane collaboration, Oxford, England). A *p* value of less than 0.05 was considered as statistical significant.

Results {#s3}
=======

The derivation of the databases and published articles is described in [Figure 1](#pone-0057854-g001){ref-type="fig"}. A total of one hundred and seventy-seven studies concerning the stroke risk associated with the use of antihypertensive agents in the patients with hypertension were identified. Among them, one hundred and forty-six studies were excluded for (1) No numbers of hypertension- and stroke-cases; (2) Data duplication; (3) Not written in English or Chinese; (4) No randomized controlled trials; (5) Data missing or lacking; (6) No control group. Therefore, thirty-one studies [@pone.0057854-National1]--[@pone.0057854-Hansson1], [@pone.0057854-Staessen1]--[@pone.0057854-Schrader1] and a total of 273,543 participants (including 130,466 experimental subjects and 143,077 controls) matched the inclusion criteria and were selected for the statistical test; and a total of 9,550 stroke events (4,145 in experimental group and 5,405 in control group) were reported (see [Table 1](#pone-0057854-t001){ref-type="table"}). The quantity and quality of original investigations play an important role in determining the quality of the meta-analysis. To controlling the publication bias, the funnel test was performed (see [Figure 2](#pone-0057854-g002){ref-type="fig"}). No evidence of publication bias was found for the included thirty-one studies. Our analysis also indicated that the heterogeneity between studies was not statistical significance (*p*\>0.05), therefore, the fixed effects model was used for the meta-analysis. The results of quality assessment for each included study indicated that among the included thirty-one studies, twenty-eight reports [@pone.0057854-National1]--[@pone.0057854-Hansson1], [@pone.0057854-Staessen1]--[@pone.0057854-Liu2], [@pone.0057854-Rothwell1]--[@pone.0057854-Dens1], [@pone.0057854-ALLHAT1]--[@pone.0057854-Borhani1], [@pone.0057854-Zanchetti2]--[@pone.0057854-Schrader1] were high quality and the remaining three studies [@pone.0057854-PooleWilson1], [@pone.0057854-Gong1], [@pone.0057854-Malacco1] were moderate quality (see [Table 1](#pone-0057854-t001){ref-type="table"} and Supplementary Information online). The overall quality of the evidence was high in our statistical tests.

![Funnel plots of odds ratios for all studies in the meta-analyses.\
(**a**) Calcium channel blockers vs Placebo, (**b**) Calcium channel blockers vs ACEIs, and (**c**) Calcium channel blockers vs Diuretics or/and β blockers. No evidence of publication bias was found in any of them.](pone.0057854.g002){#pone-0057854-g002}
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###### Characteristics of 31 randomized controlled trials included in the meta-analyses.

![](pone.0057854.t001){#pone-0057854-t001-1}

  Source year \[reference\]                                  Ethnicity                Treatment                Cases of Hypertension   Age of Cases (Mean±SD)   Years of followed up   Cases of Stroke   Incidence of Stroke (%)   Quality of the evidence   Overall risk of bias assessment                          
  --------------------------------------------------------- ----------- ------------------------------------- ----------------------- ------------------------ ---------------------- ----------------- ------------------------- ------------------------- --------------------------------- ----- ------ ---------- ---------
  **CCBs vs Placebo**                                                                                                                                                                                                                                                                                                 
  Poole-Wilson PA et al 2004 [@pone.0057854-PooleWilson1]     Europe            Nifedipine vs Placebo                3825(80)                 3840(79)                63.5±9.3            63.4±9.3                ≥4.9                       77                            99                   2    2.6    Moderate    High
  Lubsen J et al 2005 [@pone.0057854-Lubsen1]                 Europe            Nifedipine vs Placebo                  1795                     2002                  61.8±9.4            65.0±8.9                ≥5.5                       123                           171                 6.9   8.5      High       Low
  Turnbull F 2003 [@pone.0057854-Turnbull1]                   Europe               CCBs vs Placebo                     3794                     3688                     65                  65                    ≥4                        76                            119                  2    3.2      High     Unclear
  Liu L et al 2005 [@pone.0057854-Liu3]                        Asia             Felodipine vs Placebo               4841(61.8)               4870(60.5)               61.5±7.1            61.5±7.2                ≥3.5                       177                           251                 3.7   5.2      High       Low
  Berl T et al 2003 [@pone.0057854-Berl1]                     Europe            Amlodipine vs Placebo                 567(63)                 569(71)                 59.1±7.9            58.3±8.2                ≥2.6                       15                            26                  2.6   4.6      High       Low
  Tuomilehto J et al 1999 [@pone.0057854-Tuomilehto1]         Europe           Nitrendipine vs Placebo                 2146                     2057                    ≥60                  ≥60                   ≥2                        42                            62                   2     3       High     Unclear
  Dens JA et al 2001 [@pone.0057854-Dens1]                    Europe           Nisoldipine vs Placebo                 408(82)                 411(79)                   60±9                60±9                   ≥3                         4                             7                   1    1.7      High     Unclear
  Gong L et al 1996 [@pone.0057854-Gong1]                      Asia             Nifedipine vs Placebo                   817                     815                   66.2±5.1            66.7±5.4                ≥2.5                       16                            36                   2    4.4    Moderate    High
  Liu L et al 1998 [@pone.0057854-Liu2]                        Asia            Nitrendipine vs Placebo              1253(65.0)               1141(63.6)               66.7±5.7            66.4±5.4                 ≥4                        45                            59                  3.6   5.2      High     Unclear
  Staessen JA et al 1998 [@pone.0057854-Staessen1]            Europe           Nitrendipine vs Placebo              2398(32.5)               2297(33.8)               70.2±6.7            70.3±6.7                 ≥2                        47                            77                   2    3.4      High     Unclear
  Total                                                                                                                21844                   21690                                                                                         622                           907                 2.8   4.2              
  **CCBs vs ACEIs**                                                                                                                                                                                                                                                                                                   
  Estacio RO et al 1998 [@pone.0057854-Estacio1]              Europe          Nisoldipine vs Enalapril               235(68.1)               235(66.8)                57.2±8.2            57.7±8.4                 ≥5                        11                             7                  4.7    3       High     Unclear
  Leenen FH et al 2005 [@pone.0057854-Leenen1]                Europe          Amlodipine vs Lisinopril              9048(52.7)               9054(53.8)               66.8±7.8            66.8±7.8                 ≥4                        377                           457                 4.2    5       High       Low
  Fukui T et al 2003 [@pone.0057854-Fukui1]                    Asia           Amlodipine vs Candesartan                2349                     2354                   20--85              20--85                 ≥3.2                       60                            47                  2.6    2       High     Unclear
  Song Y et al 2011 [@pone.0057854-Song1]                      Asia       Levamlodipine Beaylate vs Enapril          69(52.2)                 68(51.5)               63.32±6.15          61.85±5.19                ≥1                         9                            11                  13    16.2     High     Unclear
  Tatti P et al 1998 [@pone.0057854-Tatti1]                   Europe          Amlodipine vs Fosinopril               191(55.5)               189(63.5)                62.8±0.5            63.3±0.4                ≥3.5                       10                             4                  5.2   2.1      High     Unclear
  Hansson L et al 1999 [@pone.0057854-Hansson2]               Europe                CCBs vs ACEIs                   2196(34.0)               2205(33.7)                 75.9                76.1                   ≥5                        207                           215                  1    9.8      High       Low
  Schrader J et al 2005 [@pone.0057854-Schrader1]             Europe         Nitrendipine vs Eprosartan             671 (54.8)               681(53.6)               67.7±10.4            68.1±9.5                ≥2.5                       39                            31                  5.8   4.6      High       Low
  Ekbom T et al 2004 [@pone.0057854-Ekbom1]                   Europe                CCBs vs ACEIs                    752(26.6)               772(26.8)                  76.5                76.6                   ≥5                        15                            16                   2    2.1      High     Unclear
  Total                                                                                                                15511                   15558                                                                                         728                           788                 4.7   5.1              
  **CCBs vs β** **blockers or/and Diuretics**                                                                                                                                                                                                                                                                         
  ALLHAT 2002 [@pone.0057854-ALLHAT1]                         Europe        Amlodipine vs Chlorthalidone            9048(52.7)              15255(53.0)               66.9±7.7            66.9±7.7                ≥4.9                       377                           675                 4.2   4.4      High       Low
  Rothwell PM et al 2010 [@pone.0057854-Rothwell1]            Europe           Amlodipine vs Atenolol                  9302                     9228                   40--78              40--78                  ≥2                        279                           350                  3    3.8      High       Low
  Dahlöf B et al 2005 [@pone.0057854-Dahlf1]                  Europe           Amlodipine vs Atenolol                9639(77)                 9618(77)                63.0±8.5            63.0±8.5                ≥5.5                       327                           422                 3.4   4.4      High     Unclear
  Turnbull F 2003 [@pone.0057854-Turnbull1]                   Europe       CCBs vs diuretic and β blocker              31031                   37418                     65                  65                    ≥4                        999                          1358                 3.2   3.6      High     Unclear
  Black HR et al 2003 [@pone.0057854-Black1]                  Europe          Verapamil vs Atenolol and             8179(43.8)               8297(44.2)               65.6±7.4            65.6±7.4                 ≥3                        133                           118                 1.6   1.4      High     Unclear
                                                                                 Hydrochlorothiazide                                                                                                                                                                                                                  
  Hansson L et al 1999 [@pone.0057854-Hansson2]               Europe       CCBs vs diuretic and β blocker           2196(34.0)               2213(32.0)                 75.9                 76                    ≥5                        207                           237                 9.4   10.7     High       Low
  Brown MJ et al 2000 [@pone.0057854-Brown1]                  Europe         Nifedipine vs Co-amilozide             3157(46.1)               3164(46.6)                55--80              55--80                 ≥3.5                       67                            74                  2.1   2.3      High       Low
  Pepine CJ et al 2003 [@pone.0057854-Pepine1]                Europe            Verapamil vs Atenolol               11267(48.1)             11309(47.7)               66.0±9.7            66.1±9.8                 ≥4                        176                           201                 1.6   0.2      High       Low
  Borhani NO et al 1996 [@pone.0057854-Borhani1]              Europe      Isradipine vs Hydrochlorothiazide          442(79.9)               441(75.7)                58.2±8.3            58.7±8.7                 ≥3                         6                             3                  0.1   0.07     High       Low
  Wang Y et al 1998 [@pone.0057854-Wang1]                      Asia           Nitrendipine vs Diuretics              141(62.4)               120(63.3)                 56±11                54±13                 ≥5.1                        0                             3                   0    2.5      High       Low
  Hansson L et al 2000 [@pone.0057854-Hansson1]               Europe     Diltiazem vs Diuretic and β-blocker        5410(48.5)               5471(48.7)               60.5±6.5            60.3±6.5                ≥4.5                       159                           196                 2.9   3.6      High       Low
  NICS-EH Study Group 1999 [@pone.0057854-National1]           Asia       Nicardipine vs Trichlormethiazide          204(40.2)               210(26.2)                69.7±6.5            69.9±6.4                ≥4.2                        1                             0                  0.5    0       High       Low
  Malacco E et al 2003 [@pone.0057854-Malacco1]               Europe        Lacidipine vs Chlorthalidone             942(39.6)               940(37.8)                72.3±7.5            72.4±7.6                 ≥5                        37                            38                   4     4     Moderate    High
  Ekbom T et al 2004 [@pone.0057854-Ekbom1]                   Europe       CCBs vs diuretic and β blocker            752(26.6)               756(21.8)                  76.5                76.6                   ≥5                        15                            20                   2    2.6      High       Low
  Zanchetti A et al 2002 [@pone.0057854-Zanchetti1]           Europe           Lacidipine vs Atenolol               1177(54.2)               1157(55.4)               55.9±7.5            56.1±7.5                 ≥4                         9                            14                  0.8   1.2      High       Low
  Zanchetti A et al 1998 [@pone.0057854-Zanchetti2]           Europe         Verapamil vs Chlorthalidone             224(53.1)               232(51.3)                54.2±6.8            53.9±7.2                 ≥2                         3                             1                  1.3   0.4      High     Unclear
  Total                                                                                                                93111                   105829                                                                                       2795                          3710                  3    3.5              
                                                                                                                                                                                                                                                                                                                      
  **Overall**                                                                                                       **130466**               **143077**                                                                                   **4145**                      **5405**                                      

CCBs: Calcium Channel Blockers; ACEIs: Angiotensin-Converting Enzyme Inhibitors.

GRADE Working Group grades of evidence (see Supplementary Information online). High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

The risk of bias assessment is done using RevMan (see Supplementary Information online). Low risk of bias: Plausible bias unlikely to seriously alter the results, low risk of bias for all key domains (within a study), and most information is from studies at low risk of bias (across studies). Unclear risk of bias: That raises some doubt about the results, unclear risk of bias for one or more key domains (within a study), and most information is from studies at low or unclear risk of bias (across studies). High risk of bias: Plausible bias that seriously weakens confidence in the results, high risk of bias for one or more key domains (within a study), the proportion of information from studies at high risk of bias is sufficient to affect the interpretation of results (across studies).

The issue of lost to follow-up or withdrew was identified as follows: 1) six studies [@pone.0057854-Song1], [@pone.0057854-Wang1], [@pone.0057854-Hansson2], [@pone.0057854-Borhani1], [@pone.0057854-Zanchetti2], [@pone.0057854-Berl1] reported that no patient was lost to follow-up or withdrew; 2) eight studies [@pone.0057854-Lubsen1], [@pone.0057854-Rothwell1]--[@pone.0057854-Ekbom1], [@pone.0057854-Turnbull1], [@pone.0057854-Dens1], [@pone.0057854-Estacio1]--[@pone.0057854-Fukui1], [@pone.0057854-Tuomilehto1] did not report the information of the patient's follow-up or withdrew; 3) the remaining seventeen studies [@pone.0057854-National1], [@pone.0057854-Hansson1], [@pone.0057854-Staessen1]--[@pone.0057854-Tatti1], [@pone.0057854-Liu2]--[@pone.0057854-PooleWilson1], [@pone.0057854-Dahlf1]--[@pone.0057854-Zanchetti1], [@pone.0057854-Gong1]--[@pone.0057854-Black1], [@pone.0057854-Brown1]--[@pone.0057854-Pepine1], [@pone.0057854-Malacco1], [@pone.0057854-Schrader1] reported that some patients were lost to follow-up or withdrew but not gave out the reasons, and the rate of lost to follow-up was not significantly difference between the experimental and control groups (see Supplementary Information online). Therefore, we did not perform the comparisons of incidence of withdrawals due to adverse effects for CCBs versus other drugs, because it was easy to result in a bias.

The results from the risk of bias assessment for each included study indicated that among the included thirty-one studies, fifteen reports [@pone.0057854-National1], [@pone.0057854-Hansson1], [@pone.0057854-Lubsen1], [@pone.0057854-Rothwell1], [@pone.0057854-Leenen1]--[@pone.0057854-Zanchetti1], [@pone.0057854-ALLHAT1], [@pone.0057854-Hansson2]--[@pone.0057854-Malacco1], [@pone.0057854-Berl1], [@pone.0057854-Schrader1] were low risk of bias, thirteen reports [@pone.0057854-Song1], [@pone.0057854-Staessen1], [@pone.0057854-Tatti1], [@pone.0057854-Liu2], [@pone.0057854-Ekbom1], [@pone.0057854-Dahlf1], [@pone.0057854-Turnbull1], [@pone.0057854-Dens1], [@pone.0057854-Black1], [@pone.0057854-Zanchetti2]--[@pone.0057854-Fukui1], [@pone.0057854-Tuomilehto1] were unclear risk of bias, and the remaining three studies [@pone.0057854-PooleWilson1], [@pone.0057854-Gong1], [@pone.0057854-Malacco1] were high risk of bias (see [Table 1](#pone-0057854-t001){ref-type="table"} and Supplementary Information online).

There are two types of stroke, ischemic stroke (80%) and hemorrhagic stroke (20%). A total of 60--80% of hypertension patients (blood pressure \>140/90 mmHg) face the risk of stroke. Hypertension is associated with ischemic- and hemorrhagic-stroke [@pone.0057854-Donovan1]. The detailed information of ischemic- or hemorrhagic-stroke was not presented in most original studies. The authors of included thirty-one studies have contact. Six reports authors could not contacted, nine reports authors did not response to us, five reports authors responded to us with the information we need, and eleven reports authors responded to us but did not give back the information we need. Therefore, we can not perform sub-groups analysis.

Stroke Events of CCBs vs Placebo {#s3a}
--------------------------------

Ten studies were included in this test [@pone.0057854-Staessen1], [@pone.0057854-Lubsen1]--[@pone.0057854-PooleWilson1], [@pone.0057854-Liu3], [@pone.0057854-Turnbull1], [@pone.0057854-Dens1]--[@pone.0057854-Gong1], [@pone.0057854-Berl1]--[@pone.0057854-Tuomilehto1], which consisted of 21,844 experimental subjects and 21,690 controls, and 1,574 stroke events (622 in experimental group and 907 in control group). Statistic test revealed that the CCBs could significantly decline the stroke risk (OR = 0.68, 95% CI 0.61--0.75, p\<1×10^−5^) compared with that of placebo (see [Figure 3a](#pone-0057854-g003){ref-type="fig"}). The incidence of stroke in CCBs group was decreased by 33.33% \[(4.2%-2.8%) ÷ 4.2% × 100%\] compared with that of placebo group (see [Table 1](#pone-0057854-t001){ref-type="table"}).

![OR and 95% CI of individual studies and pooled data against stroke in the patients with hypertension.\
(**a**) Calcium channel blockers vs Placebo, (**b**) Calcium channel blockers vs ACEIs, and (**c**) Calcium channel blockers vs Diuretics or/and β Blockers.](pone.0057854.g003){#pone-0057854-g003}

Stroke Events of CCBs vs ACEIs {#s3b}
------------------------------

Eight studies with a total of 15,511 experimental subjects and 15,558 controls were included in this analysis [@pone.0057854-Song1], [@pone.0057854-Tatti1], [@pone.0057854-Ekbom1], [@pone.0057854-Leenen1], [@pone.0057854-Hansson2], [@pone.0057854-Estacio1]--[@pone.0057854-Fukui1], [@pone.0057854-Schrader1], and 1446 stroke events were reported (728 in experimental group and 788 in control group). No statistically significant difference was found (OR = 0.92, 95% CI 0.8--1.02, p = 0.12) between CCBs and ACEIs in their efficiency of against stroke (see [Figure 3b](#pone-0057854-g003){ref-type="fig"}). However, the incidence of stroke in CCBs group was decreased by 7.84% \[(5.1%-4.7%) ÷ 5.1% × 100%\] compared with that of ACEIs group (see [Table 1](#pone-0057854-t001){ref-type="table"}).

Stroke Events of CCBs vs Diuretics or/and β-adrenergic Blockers {#s3c}
---------------------------------------------------------------

Sixteen independent reports with 93,111 experimental subjects and 105,829 controls were included in this meta-analysis [@pone.0057854-National1], [@pone.0057854-Hansson1], [@pone.0057854-Rothwell1]--[@pone.0057854-Dahlf1], [@pone.0057854-Zanchetti1]--[@pone.0057854-Wang1], [@pone.0057854-ALLHAT1]--[@pone.0057854-Zanchetti2], which consisted of 6,505 stroke events (2795 in experimental group and 3710 in control group). The incidence of stroke in CCBs group was decreased by 14.28% \[(3.5%-3%) ÷ 3.5% × 100%\] compared with that of diuretics or/and β-adrenergic blockers group (see [Table 1](#pone-0057854-t001){ref-type="table"}), and the CCBs were more effective (OR = 0.87, 95% CI 0.83--0.92, p\<1×10^−5^) than diuretics or/and β blockers in the prevention of stroke (see [Figure 3c](#pone-0057854-g003){ref-type="fig"}). Results of subgroups analyses indicated that the CCBs were more effective than β-adrenergic blockers alone (OR = 0.79, 95% CI 0.72--0.87, p\<1×10^−5^), β-adrenergic blockers combined with diuretics (OR = 0.89, 95% CI 0.83--0.95, p = 7×10^−5^), but not diuretics alone (OR = 0.95, 95% CI 0.84--1.07, p = 0.39) in the prevention of stroke (see [Figure 3c](#pone-0057854-g003){ref-type="fig"}).

Discussion {#s4}
==========

This study demonstrates that the use of calcium channel blockers therapy, compared with placebo therapy (OR, 0.68), β-adrenergic blockers therapy (OR, 0.79), diuretics combined with β-adrenergic blockers therapy (OR, 0.89), angiotensin-converting enzyme inhibitors therapy (OR, 0.92), and diuretics therapy (OR, 0.95), was associated with a lower incidence of stroke events in the patients with hypertension. In this combined study of different hypertension populations, the risk of stroke events reduction for patients receiving calcium channel blockers therapy was similar. Due to different sample size in different treatment groups, it is essential to use and interpret the above results with cautions. These findings present new evidence to support the idea that the CCBs reduced stroke more than placebo and β-adrenergic blockers but were not different than ACEIs and diuretics. Hypertension is only one of the major risk factors in the development of stroke, the number of stroke events remains high even though the antihypertensive agents are used extensively [@pone.0057854-Schrader1]. Therefore, other risk factors or/and the biological processes underlying the pathophysiology of stroke warrant further studies in the near future.

The findings of our work indicated that CCBs reduced stroke more than placebo and β-adrenergic blockers, but the detail molecular mechanisms are not well known and remain to be excavated in the future. By now, it can be explained in part by that CCBs can generate stronger antihypertensive effect (by dilating the blood vessels) than that of beta-blockers (by reducing the blood flow of cardiac output) or that of placebo (by confounders). These results reported here provide strong evidence linking controlling hypertension to a reduced risk of stroke. Meanwhile, this study has some limitations and caveats. First, as not all clinical data were available from each original report, other subclasses-stratified analyses could not be performed; the risk of bias assessment in this work could rob the credibility of results. Second, only studies reported in English or Chinese were included, which might be vulnerable to the bias of language and ethnicity. Third, the whole sample size in this study is sufficient for statistic purposes, but the sample size of each subgroup is relatively small and susceptible to false positive or negative results. Fourth, after the treatment of antihypertensive agents, the years of followed-up between studies varied greatly (from 1 to 5.5 years), which also could result in a bias. Finally, only four kinds of antihypertensive agents were tested in this report; addition of other drugs and withdrawals of treatment may also lead to an underestimation of the real differences in stroke risk between the previous reports. Further studies are required to investigate the association between other antihypertensive agents and stroke-risk, and to provide a better estimate the benefits of antihypertensive agents against stroke in the hypertension populations.

In conclusions, the present analysis shows that CCBs, ACEIs, diuretics, and β-adrenergic blockers can decline the incidence of stroke in the hypertension populations. Among them, CCBs reduced stroke more than placebo and β-adrenergic blockers, but were not different than ACEIs and diuretics. More head to head RCTs are warranted. This systematic review and meta-analysis provides a thorough examination of the literature on the effect of first-line antihypertensive agents in the prevention of stroke, and provide a foundation of knowledge on which clinical and public health messaging deserves to be further discussed.
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